Marker Therapeutics, Inc.

+1 (713) 400-6400

3200 Southwest Fwy #2240 Phoenix Tower
Houston, TX 77027

© 2019 Marker Therapeutics, Inc.

A major leap forward in cell therapy

Learn More

Pancreatic Cancer Interim Results

The Company

We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Recognition

Marker Therapeutics, Inc. Congratulates Dr. James P. Allison for Receiving the 2018 Nobel Prize in Medicine or Physiology

Marker Therapeutics, Inc. Congratulates Dr. Padmanee Sharma for Receiving the William B. Coley Award for Distinguished Research in Tumor Immunology

At the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, Baylor College of Medicine Presented Data on Several Baylor Clinical Trials Employing Technology Exclusively Licensed to Marker

Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results

Conference Call and Webcast Today at
5:00pm EST

Houston, TX – November 12, 2019 – Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2019.

Read more

Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019

Houston, TX – November 11, 2019 –  Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Tuesday, November 12, 2019 at 5:00 p.m.

Read more

Clinical Studies

Marker has multiple clinical studies ongoing and planned for its multi-antigen T cell therapies. Target indications include acute myelogenous leukemia (AML), non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and breast cancer.

Technology

Marker’s unique cell therapy platform is the first to successfully target multiple tumor-associated antigens simultaneously, without the need for genetic modification of patients’ T cells. The result is a remarkably robust and durable anti-tumor immune response and a manufacturing process that is simpler and less costly than today’s TCR and CAR-T therapy.

Pipeline

Marker has a deep pipeline of clinical-stage programs that leverage the company’s unique multi-TAA cell therapy platform, addressing multiple hematologic malignancies and solid tumors. The company is also advancing its novel peptide vaccine in breast and ovarian cancer.

Management Team

Marker is led by an executive management team specialized in cancer immunotherapy, bringing together extensive corporate, clinical, translational and medical experience. With its world-class scientific advisors, Marker is well positioned to advance its science-based approach to transforming the cell therapy landscape.

Sign up for email alerts

Get Marker News Delivered To Your Inbox

Sign Up Today

© 2019 Marker Therapeutics, Inc.